Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients

• Status: Not yet recruiting
• Trial end date: 2023-07-01

Summary

The goal of this clinical trial is to compare blood-sugar and blood circulatory system risk-position in type 2 diabetes patients on voglibose versus those on glybenclamide when the two drugs are added to metformin because metformin alone is not controlling the blood-sugar well. The results of this trial will help in improving the health and treatment results of the type 2 diabetic patients.

The main question the trial aims to answer is whether there is a difference in blood-sugar and blood circulatory system treatment results between voglibose + metformin and glibenclamide + metformin treatment combinations.

Participants that agree to participate in the trial will be asked to provide a sample of blood so that the following measurable laboratory factors will be used to compare any differences in treatment results between the two treatment groups from the beginning to the end of the trial:

• Total Cholesterol (TC),

• Low Density Lipoproteins (LDL-c),

• High Density Lipoproteins (HDL-c),

• Fasting Triglycerides (FTG),

• Fasting blood sugar (FBS),

• Post prandial blood sugar (PPBG),

• Glycated hemoglobin (HbA1c) correlated to hemoglobin level,

• creatinine,

• blood urea and

• electrolytes (K+, Na+, Cl-).

• Phase: Phase 3

Details

• Lead Sponsor: University of Zambia
• Collaborator: University Teaching Hospital, Lusaka, Zambia
• Treatments: Glyburide; Metformin; Voglibose